Driving Action: Innovation and Access for a Resilient Response Against AMR

2024 is a significant year for addressing the urgency of Antimicrobial Resistance (AMR), which requires a broad, multi-stakeholder approach. Alarming statistics underpin the need for prompt action. In 2019, AMR was responsible for 1.27 million deaths and contributed to nearly five million overall. It’s a crisis that impacts every aspect of modern medicine, from surgery to cancer care.

The challenge is related not only to strengthening innovation but also to ensuring sustainable and appropriate access to both existing and new antibiotics, which requires a concerted approach to addressing the many interconnected challenges.

This session will delve into perspectives on the critical need for developing new antibiotics to treat resistant infections, and explore the path forward for concrete solutions to improve the innovation outlook and patient access. It will also explore how to maintain this priority high on the upcoming G7/G20 agendas.